share_log

英诺特(688253.SH):2022年呼吸道系列中非新冠系列营业收入为1.17亿元,毛利率为80%左右

Innote (688253.SH): The 2022 respiratory series's revenue for the non-COVID-19 series was 117 million yuan, and the gross margin was about 80%

Gelonghui Finance ·  Dec 26, 2023 01:28

On December 26, Gelonghui (688253.SH) said on the investor interactive platform that the company's 2022 respiratory series, China-Africa COVID-19 series, revenue was 117.1369 million yuan, and gross margin was around 80%.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment